Author

M. Kovar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Drobek· 1 shared E. K. Leonard· 1 shared E. R. Johansen· 1 shared H. Rossez· 1 shared H. Vecerova· 1 shared I. Malatova· 1 shared J. B. Spangler· 1 shared J. Kovarova· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Drobek

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity

E. K. Leonard, J. Tomala, J. R. Gould, M. I. Leff, J.-X. Lin, P. Lin, M. J. Porter, E. R. Johansen, L. Thompson, S. D. Cao, T. Henclova, M. Huliciak, O. Vanek, M. Kovar, W. J. Leonard, J. B. Spangler

This paper develops an IL-2/antibody fusion protein that enhances immune effector cell activation and antitumor activity while reducing toxicity compared to natural IL-2.

bioRxiv · May 3, 2023Bioengineering

Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2

O. Tsyklauri, T. Chadimova, V. Niederlova, J. Kovarova, J. Michalik, I. Malatova, S. Janusova, O. Ivashchenko, H. Rossez, A. Drobek, H. Vecerova, V. Galati, M. Kovar, O. Stepanek

This study identifies Tregs suppressing KLRK1+ IL7R+ CD8+ effector T cells by limiting IL-2, which enhances autoimmunity and anti-tumor responses.

bioRxiv · Nov 10, 2021Immunology